A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer

BACKGROUND: Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, which is an effective treatment for patients with non-small cell lung cancer (NSCLC), especially those harboring activating EGFR mutations. A previous phase III trial suggested that patients with EGFR wild...

Descripción completa

Detalles Bibliográficos
Autores principales: Minemura, Hiroyuki, Yokouchi, Hiroshi, Azuma, Keisuke, Hirai, Ken-ichiro, Sekine, Satoko, Oshima, Kengo, Kanazawa, Kenya, Tanino, Yoshinori, Inokoshi, Yayoi, Ishii, Taeko, Katsuura, Yutaka, Oishi, Akio, Ishida, Takashi, Munakata, Mitsuru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467621/
https://www.ncbi.nlm.nih.gov/pubmed/26043909
http://dx.doi.org/10.1186/s13104-015-1214-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467621/
https://www.ncbi.nlm.nih.gov/pubmed/26043909
http://dx.doi.org/10.1186/s13104-015-1214-9

Ejemplares similares